APO RESEARCH · REPORT
Acinetobacter Infections Treatment
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Product & engineering
Understand the product.
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
Selected research
Industry Research
Acinetobacter Infections Treatment Industry Research Report 2026
Market perspective
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
Read the full market overview
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
Report Scope
This report quantifies the global Acinetobacter Infections Treatment market in terms of revenue (US$ million) and, where applicable, service volume (Cases), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Cases) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acinetobacter Infections Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acinetobacter Infections Treatment Market by Company
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Acinetobacter Infections Treatment Segment by Type
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Acinetobacter Infections Treatment Segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
Acinetobacter Infections Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Acinetobacter Infections Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sulbactam
- Carbapenems
- Aminoglycosides
- Polymyxins
- Tetracyclines
- Others
Applications
- ETX2514
- Nacubactam RG6080
- Arenicin
- VXD-001
- Small Molecule Antibiotic
- AR-401 mAB
- LCB01-0371 (PO)
- GN-4474
- Antibacterial Antibody
- Others
Companies covered
- Entasis Therapeutics
- Roche
- Adenium Biotech
- Vaxdyn
- Hsiri Therapeutics
- Aridis Pharmaceuticals
- LegoChem Biosciences
- Atterx Biotherapeutics
- Achaogen
- Peptilogics
- Sealife PHARMA
- Shionogi
- Techulon
- Tetraphase Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Acinetobacter Infections Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Sulbactam
- 2.2.3 Carbapenems
- 2.2.4 Aminoglycosides
- 2.2.5 Polymyxins
- 2.2.6 Tetracyclines
- 2.2.7 Others
- 2.3 Acinetobacter Infections Treatment by Pipeline
- 2.3.1 Market Value Comparison by Pipeline (2021 VS 2025 VS 2032)
- 2.3.2 ETX2514
- 2.3.3 Nacubactam RG6080
- 2.3.4 Arenicin
- 2.3.5 VXD-001
- 2.3.6 Small Molecule Antibiotic
- 2.3.7 AR-401 mAB
- 2.3.8 LCB01-0371 (PO)
- 2.3.9 GN-4474
- 2.3.10 Antibacterial Antibody
- 2.3.11 Others
- 2.4 Assumptions and Limitations
3 Acinetobacter Infections Treatment Breakdown Data by Type
- 3.1 Global Acinetobacter Infections Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Type (2027-2032)
4 Acinetobacter Infections Treatment Breakdown Data by Pipeline
- 4.1 Global Acinetobacter Infections Treatment Historic Market Size by Pipeline (2021-2026)
- 4.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Pipeline (2027-2032)
5 Global Growth Trends
- 5.1 Global Acinetobacter Infections Treatment Market Perspective (2021-2032)
- 5.2 Global Acinetobacter Infections Treatment Growth Trends by Region
- 5.2.1 Global Acinetobacter Infections Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Acinetobacter Infections Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Acinetobacter Infections Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Acinetobacter Infections Treatment Market Dynamics
- 5.3.1 Acinetobacter Infections Treatment Industry Trends
- 5.3.2 Acinetobacter Infections Treatment Market Drivers
- 5.3.3 Acinetobacter Infections Treatment Market Challenges
- 5.3.4 Acinetobacter Infections Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Acinetobacter Infections Treatment Players by Revenue
- 6.1.1 Global Top Acinetobacter Infections Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Acinetobacter Infections Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Acinetobacter Infections Treatment Head Office and Area Served
- 6.4 Global Acinetobacter Infections Treatment Players, Product Type & Application
- 6.5 Global Acinetobacter Infections Treatment Manufacturers Established Date
- 6.6 Global Acinetobacter Infections Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Acinetobacter Infections Treatment Market Size (2021-2032)
- 7.2 North America Acinetobacter Infections Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Acinetobacter Infections Treatment Market Size by Country (2021-2026)
- 7.4 North America Acinetobacter Infections Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Acinetobacter Infections Treatment Market Size (2021-2032)
- 8.2 Europe Acinetobacter Infections Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Acinetobacter Infections Treatment Market Size by Country (2021-2026)
- 8.4 Europe Acinetobacter Infections Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Acinetobacter Infections Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Acinetobacter Infections Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Acinetobacter Infections Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Acinetobacter Infections Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Acinetobacter Infections Treatment Market Size (2021-2032)
- 10.2 South America Acinetobacter Infections Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Acinetobacter Infections Treatment Market Size by Country (2021-2026)
- 10.4 South America Acinetobacter Infections Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Acinetobacter Infections Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Acinetobacter Infections Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Entasis Therapeutics
- 12.1.1 Entasis Therapeutics Company Information
- 12.1.2 Entasis Therapeutics Business Overview
- 12.1.3 Entasis Therapeutics Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio
- 12.1.5 Entasis Therapeutics Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.2.4 Roche Acinetobacter Infections Treatment Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Adenium Biotech
- 12.3.1 Adenium Biotech Company Information
- 12.3.2 Adenium Biotech Business Overview
- 12.3.3 Adenium Biotech Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio
- 12.3.5 Adenium Biotech Recent Developments
- 12.4 Vaxdyn
- 12.4.1 Vaxdyn Company Information
- 12.4.2 Vaxdyn Business Overview
- 12.4.3 Vaxdyn Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio
- 12.4.5 Vaxdyn Recent Developments
- 12.5 Hsiri Therapeutics
- 12.5.1 Hsiri Therapeutics Company Information
- 12.5.2 Hsiri Therapeutics Business Overview
- 12.5.3 Hsiri Therapeutics Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
- 12.5.5 Hsiri Therapeutics Recent Developments
- 12.6 Aridis Pharmaceuticals
- 12.6.1 Aridis Pharmaceuticals Company Information
- 12.6.2 Aridis Pharmaceuticals Business Overview
- 12.6.3 Aridis Pharmaceuticals Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
- 12.6.5 Aridis Pharmaceuticals Recent Developments
- 12.7 LegoChem Biosciences
- 12.7.1 LegoChem Biosciences Company Information
- 12.7.2 LegoChem Biosciences Business Overview
- 12.7.3 LegoChem Biosciences Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
- 12.7.5 LegoChem Biosciences Recent Developments
- 12.8 Atterx Biotherapeutics
- 12.8.1 Atterx Biotherapeutics Company Information
- 12.8.2 Atterx Biotherapeutics Business Overview
- 12.8.3 Atterx Biotherapeutics Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
- 12.8.5 Atterx Biotherapeutics Recent Developments
- 12.9 Achaogen
- 12.9.1 Achaogen Company Information
- 12.9.2 Achaogen Business Overview
- 12.9.3 Achaogen Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
- 12.9.5 Achaogen Recent Developments
- 12.10 Peptilogics
- 12.10.1 Peptilogics Company Information
- 12.10.2 Peptilogics Business Overview
- 12.10.3 Peptilogics Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
- 12.10.5 Peptilogics Recent Developments
- 12.11 Sealife PHARMA
- 12.11.1 Sealife PHARMA Company Information
- 12.11.2 Sealife PHARMA Business Overview
- 12.11.3 Sealife PHARMA Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
- 12.11.5 Sealife PHARMA Recent Developments
- 12.12 Shionogi
- 12.12.1 Shionogi Company Information
- 12.12.2 Shionogi Business Overview
- 12.12.3 Shionogi Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
- 12.12.5 Shionogi Recent Developments
- 12.13 Techulon
- 12.13.1 Techulon Company Information
- 12.13.2 Techulon Business Overview
- 12.13.3 Techulon Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
- 12.13.5 Techulon Recent Developments
- 12.14 Tetraphase Pharmaceuticals
- 12.14.1 Tetraphase Pharmaceuticals Company Information
- 12.14.2 Tetraphase Pharmaceuticals Business Overview
- 12.14.3 Tetraphase Pharmaceuticals Revenue in Acinetobacter Infections Treatment Business (2021-2026)
- 12.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
- 12.14.5 Tetraphase Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst